4808 related articles for article (PubMed ID: 4052966)
1. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
Livingston PO; Kaelin K; Pinsky CM; Oettgen HF; Old LJ
Cancer; 1985 Nov; 56(9):2194-200. PubMed ID: 4052966
[TBL] [Abstract][Full Text] [Related]
2. Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells.
Livingston PO; Takeyama H; Pollack MS; Houghton AN; Albino A; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1983 May; 31(5):567-75. PubMed ID: 6852975
[TBL] [Abstract][Full Text] [Related]
3. Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells.
Livingston PO; Watanabe T; Shiku H; Houghton AN; Albino A; Takahashi T; Resnick LA; Michitsch R; Pinsky CM; Oettgen HF; Old LJ
Int J Cancer; 1982 Oct; 30(4):413-22. PubMed ID: 7141736
[TBL] [Abstract][Full Text] [Related]
4. Serological survey of normal humans for natural antibody to cell surface antigens of melanoma.
Houghton AN; Taormina MC; Ikeda H; Watanabe T; Oettgen HF; Old LJ
Proc Natl Acad Sci U S A; 1980 Jul; 77(7):4260-4. PubMed ID: 6933476
[TBL] [Abstract][Full Text] [Related]
5. [Vaccine therapy of malignant melanoma. II. Serological evaluation of the immune responses to the injection using allogeneic melanoma cell vaccine].
Takeyama H; Watanabe T; Livingston PO
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1624-33. PubMed ID: 6870307
[TBL] [Abstract][Full Text] [Related]
6. Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody.
Real FX; Mattes MJ; Houghton AN; Oettgen HF; Lloyd KO; Old LJ
J Exp Med; 1984 Oct; 160(4):1219-33. PubMed ID: 6237165
[TBL] [Abstract][Full Text] [Related]
7. Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells.
Livingston PO; Albino AP; Chung TJ; Real FX; Houghton AN; Oettgen HF; Old LJ
Cancer; 1985 Feb; 55(4):713-20. PubMed ID: 2981601
[TBL] [Abstract][Full Text] [Related]
8. [Serological analysis of melanoma patients receiving autologous melanoma cell vaccines].
Watanabe T
Gan To Kagaku Ryoho; 1983 Feb; 10(2 Pt):261-72. PubMed ID: 6881976
[TBL] [Abstract][Full Text] [Related]
9. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma.
Mittelman A; Chen GZ; Wong GY; Liu C; Hirai S; Ferrone S
Clin Cancer Res; 1995 Jul; 1(7):705-13. PubMed ID: 9816036
[TBL] [Abstract][Full Text] [Related]
10. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
Thatcher N; Hashmi K; Chang J; Swindell R; Crowther D
Cancer; 1980 Sep; 46(6):1378-82. PubMed ID: 7417939
[TBL] [Abstract][Full Text] [Related]
11. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens.
Albino AP; Lloyd KO; Houghton AN; Oettgen HF; Old LJ
J Exp Med; 1981 Dec; 154(6):1764-78. PubMed ID: 6976407
[TBL] [Abstract][Full Text] [Related]
14. Humoral response of melanoma patients to two different tumor-associated antigens.
Chee DO; Gupta RK; Morton DL
J Surg Oncol; 1983 Aug; 23(4):228-35. PubMed ID: 6876798
[TBL] [Abstract][Full Text] [Related]
15. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside.
Livingston PO; Wong GY; Adluri S; Tao Y; Padavan M; Parente R; Hanlon C; Calves MJ; Helling F; Ritter G
J Clin Oncol; 1994 May; 12(5):1036-44. PubMed ID: 8164027
[TBL] [Abstract][Full Text] [Related]
16. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A1-, MAGE-A10-, and gp100-derived peptides are immunogenic when combined with granulocyte-macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma.
Chianese-Bullock KA; Pressley J; Garbee C; Hibbitts S; Murphy C; Yamshchikov G; Petroni GR; Bissonette EA; Neese PY; Grosh WW; Merrill P; Fink R; Woodson EM; Wiernasz CJ; Patterson JW; Slingluff CL
J Immunol; 2005 Mar; 174(5):3080-6. PubMed ID: 15728523
[TBL] [Abstract][Full Text] [Related]
19. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
20. Establishment of paired tumor cells and autologous virus-transformed cell lines to define humoral immune responses in melanoma and sarcoma patients.
Saxton RE; Irie RF; Ferrone S; Pellegrino MA; Morton DL
Int J Cancer; 1978 Mar; 21(3):299-306. PubMed ID: 204583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
